Risk-stratified surveillance for individuals in the UK at high risk of developing pancreatic cancer: Outcomes from the European Registry of Hereditary Pancreatic Diseases (EUROPAC)

Gastrointestinal Cancer

Treatment landscape from first- to third-line therapy and quality of life data of patients with pancreatic cancer from the prospective German PARAGON (Platform for Outcome, Quality of Life, and Translational Research on Pancreatic Cancer) registry (IKF-PARAGON study)

Int J Cancer

Goetze TO, Al-Batran SE, Liersch R, Scheuer L, Goehler T, Kaiser U, Denzlinger C, Brandl S, Pink D, Uhlig J, Maasberg M, Loose M, Schaaf M, Sookthai D, Zäpf B, Pauligk C, Habibzade T, Hofheinz RD, Koch C, AIO Study Group

doi: 10.1002/ijc.70280

Gastrointestinal Cancer

Comparing short- and long-term survivors in metastatic pancreatic cancer: Insights into patient and disease profiles impacting systemic therapy outcomes

Eur J Cancer

Graus MUJE, van Diepen AE, Broekman T, van Eijck CWF, van Hooft JE, Homs MYV, Wumkes ML, Wilmink JW, de Hingh IHJT, Valkenburg-van Iersel LBJ, van der Geest LGM, Vos-Geelen J, Dutch Pancreatic Cancer Group (DPCG)

doi: 10.1016/j.ejca.2026.116263

Further Publications

Assessing quality of life in individuals with hereditary cancer risk: Results from phases 1-3a of the EORTC QLQ-HCR30 questionnaire

Eur J Cancer

Engele VI, Vassiliou V, Wheelwright S, Sztankay M, Puglisi C, Pogoda K, van Leeuwaarde R, Bleiker E, Abdel-Razeq H, Fox L, Lanceley A, Dabakuyo S, Bjelic-Radisic V, Nordin A, Ioannidis G, Kulís D, Brédart A, Schwaninger G, Arraras JI, Holzner B, Oberguggenberger AS, EORTC Quality of Life Group

doi: 10.1016/j.ejca.2026.116226

Gynecologic Cancer

Salpingectomy in individuals at high risk for tubo-ovarian cancer - consensus and precaution

Am J Obstet Gynecol

Wilke RN, Pennington KP, Gootzen TA, Steenbeek MP, de Hullu JA, Long KC, Blank SV, Swisher EM, Lu KH, Norquist B

doi: 10.1016/j.ajog.2025.10.044

Genitourinary Cancer

Patient-reported outcomes: active surveillance vs radical therapies in low-risk prostate cancer

BJU Int

Al-Nader M, Kesch C, Mahmoud O, Hadaschik BA, Fichtner J, Carl G, Feick G, Burchardt M, Zimmermanns V, Prause L, Polat B, Blana A, Horstmann M, Saar M, Miglierini P, Almansur K, Hefermehl L, Porres D, Peters I, Wiens K, Palisaar RJ, Winter A, Neisius A, Kunzmann EM, Harke NN, Bolenz C, Albarghouth MH, Manka L, Kramer M, Luger F, Knoll T, Pfitzenmaier J, Brock M, Schittko J, Sommer JP, Reichert M, Lenart S, Huber P, Hijazi S, Calderaro A, Hermanns T, Tonhauser J, Kowalski C, Sibert NT

doi: 10.1111/bju.70167

Breast Cancer

Tailoring Treatment to Cancer Risk and Patient Preference: The 2025 St Gallen International Breast Cancer Consensus Statement on Individualizing Therapy for Patients With Early Breast Cancer

Ann Oncol

Burstein HJ, Curigliano G, Gnant M, Loibl S, Regan MM, Loi S, Denkert C, Poortmans P, Cameron D, Thurlimann B, Weber WP, Panelists of the St. Gallen International Breast Cancer Consensus 2025

doi: 10.1016/j.annonc.2025.09.007

Gynecologic Cancer

Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trial

★ 3 Recommended and commented by Dr Andreas Müller, Faculty Member

★ 1 Recommended by Prof. Dr Beat Thürlimann, Faculty Member

Lancet Oncol

Post CCB, de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Leary A, Ottevanger PB, McCormack M, Khaw P, D'Amico R, Fyles A, Chargari C, Kitchener HC, Do V, Lissoni A, Provencher D, Genestie C, Nijman HW, Whitmarsh K, Jürgenliemk-Schulz IM, Feeney A, Lutgens LCHW, Bouma J, Leon-Castillo A, Nout RA, Putter H, Bosse T, Creutzberg CL

doi: 10.1016/S1470-2045(25)00379-1

Genitourinary Cancer

Impact of American Urological Association risk category on outcomes of intravesical BCG vs gemcitabine/docetaxel in high-grade Ta non-muscle-invasive bladder cancer

BJU Int

Abou Chakra M, McElree IM, Mott SL, O'Donnell MA

doi: 10.1111/bju.70149

Genitourinary Cancer

Long-term outcomes of a cascading salvage strategy for high-risk non-muscle-invasive bladder cancer

BJU Int

McElree IM, Steinberg RL, Hougen HY, Mott SL, Packiam VT, O'Donnell MA

doi: 10.1111/bju.70044

Related content

Treatment landscape from first- to third-line therapy and quality of life data of patients with pancreatic cancer from the prospective German PARAGON (Platform for Outcome, Quality of Life, and Translational Research on Pancreatic Cancer) registry (IKF-PARAGON study)

Comparing short- and long-term survivors in metastatic pancreatic cancer: Insights into patient and disease profiles impacting systemic therapy outcomes

Assessing quality of life in individuals with hereditary cancer risk: Results from phases 1-3a of the EORTC QLQ-HCR30 questionnaire

Salpingectomy in individuals at high risk for tubo-ovarian cancer - consensus and precaution

Patient-reported outcomes: active surveillance vs radical therapies in low-risk prostate cancer

Tailoring Treatment to Cancer Risk and Patient Preference: The 2025 St Gallen International Breast Cancer Consensus Statement on Individualizing Therapy for Patients With Early Breast Cancer

Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trial

Impact of American Urological Association risk category on outcomes of intravesical BCG vs gemcitabine/docetaxel in high-grade Ta non-muscle-invasive bladder cancer

Long-term outcomes of a cascading salvage strategy for high-risk non-muscle-invasive bladder cancer